Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Christian Rask-Madsen, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Christian Rask-Madsen and George King.
Connection Strength

7.314
  1. Letter by Rask-Madsen et al Regarding Article, "Selective Enhancement of Insulin Sensitivity in the Endothelium In Vivo Reveals a Novel Proatherosclerotic Signaling Loop". Circ Res. 2017 02 17; 120(4):e2-e3.
    View in: PubMed
    Score: 0.729
  2. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. 2013 Jan 08; 17(1):20-33.
    View in: PubMed
    Score: 0.548
  3. Hyperinsulinemia does not change atherosclerosis development in apolipoprotein E null mice. Arterioscler Thromb Vasc Biol. 2012 May; 32(5):1124-31.
    View in: PubMed
    Score: 0.518
  4. Endothelium-dependent delivery of insulin to muscle interstitium. Cell Metab. 2011 Mar 02; 13(3):236-8.
    View in: PubMed
    Score: 0.482
  5. Diabetes: Podocytes lose their footing. Nature. 2010 Nov 04; 468(7320):42-4.
    View in: PubMed
    Score: 0.471
  6. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab. 2010 May 05; 11(5):379-89.
    View in: PubMed
    Score: 0.455
  7. Kidney complications: factors that protect the diabetic vasculature. Nat Med. 2010 Jan; 16(1):40-1.
    View in: PubMed
    Score: 0.444
  8. More sugar, less blood vessels: another piece in the puzzle of increased cardiovascular risk in diabetes. Arterioscler Thromb Vasc Biol. 2008 Apr; 28(4):608-10.
    View in: PubMed
    Score: 0.394
  9. Differential regulation of VEGF signaling by PKC-alpha and PKC-epsilon in endothelial cells. Arterioscler Thromb Vasc Biol. 2008 May; 28(5):919-24.
    View in: PubMed
    Score: 0.392
  10. Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab. 2007 Jan; 3(1):46-56.
    View in: PubMed
    Score: 0.361
  11. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol. 2005 Mar; 25(3):487-96.
    View in: PubMed
    Score: 0.315
  12. Homozygous receptors for insulin and not IGF-1 accelerate intimal hyperplasia in insulin resistance and diabetes. Nat Commun. 2019 09 27; 10(1):4427.
    View in: PubMed
    Score: 0.218
  13. Exogenous Insulin Infusion Can Decrease Atherosclerosis in Diabetic Rodents by Improving Lipids, Inflammation, and Endothelial Function. Arterioscler Thromb Vasc Biol. 2018 01; 38(1):92-101.
    View in: PubMed
    Score: 0.192
  14. Regulation of Macrophage Apoptosis and Atherosclerosis by Lipid-Induced PKCd Isoform Activation. Circ Res. 2017 Oct 27; 121(10):1153-1167.
    View in: PubMed
    Score: 0.189
  15. SHP-1 activation inhibits vascular smooth muscle cell proliferation and intimal hyperplasia in a rodent model of insulin resistance and diabetes. Diabetologia. 2017 03; 60(3):585-596.
    View in: PubMed
    Score: 0.180
  16. Insulin decreases atherosclerosis by inducing endothelin receptor B expression. JCI Insight. 2016 May 05; 1(6).
    View in: PubMed
    Score: 0.172
  17. Serine phosphorylation sites on IRS2 activated by angiotensin II and protein kinase C to induce selective insulin resistance in endothelial cells. Mol Cell Biol. 2013 Aug; 33(16):3227-41.
    View in: PubMed
    Score: 0.141
  18. Induction of vascular insulin resistance and endothelin-1 expression and acceleration of atherosclerosis by the overexpression of protein kinase C-ß isoform in the endothelium. Circ Res. 2013 Aug 02; 113(4):418-27.
    View in: PubMed
    Score: 0.141
  19. Retinal not systemic oxidative and inflammatory stress correlated with VEGF expression in rodent models of insulin resistance and diabetes. Invest Ophthalmol Vis Sci. 2012 Dec 19; 53(13):8424-32.
    View in: PubMed
    Score: 0.136
  20. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCß activation in diabetes. Diabetes. 2012 Nov; 61(11):2967-79.
    View in: PubMed
    Score: 0.133
  21. Glomerular VEGF resistance induced by PKCd/SHP-1 activation and contribution to diabetic nephropathy. FASEB J. 2012 Jul; 26(7):2963-74.
    View in: PubMed
    Score: 0.130
  22. Inhibition of insulin signaling in endothelial cells by protein kinase C-induced phosphorylation of p85 subunit of phosphatidylinositol 3-kinase (PI3K). J Biol Chem. 2012 Feb 10; 287(7):4518-30.
    View in: PubMed
    Score: 0.127
  23. Glomerular-specific protein kinase C-ß-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity. Kidney Int. 2011 Apr; 79(8):883-96.
    View in: PubMed
    Score: 0.119
  24. Selective regulation of heme oxygenase-1 expression and function by insulin through IRS1/phosphoinositide 3-kinase/Akt-2 pathway. J Biol Chem. 2008 Dec 05; 283(49):34327-36.
    View in: PubMed
    Score: 0.102
  25. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain. FASEB J. 2006 Jun; 20(8):1203-5.
    View in: PubMed
    Score: 0.086
  26. Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes. 2006 Mar; 55(3):691-8.
    View in: PubMed
    Score: 0.085
  27. Modulating Notch signaling to enhance neovascularization and reperfusion in diabetic mice. Biomaterials. 2010 Dec; 31(34):9048-56.
    View in: PubMed
    Score: 0.029
  28. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab. 2008 Feb; 7(2):125-34.
    View in: PubMed
    Score: 0.024
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.